Literature DB >> 8777262

The pathology of cervical neoplasia.

A G Ostör1, N Mulvany.   

Abstract

The World Health Organization classification has clarified the typing of cervical tumours. The category of early stromal invasion has been eliminated from the International Federation of Gynecology and Obstetrics staging scheme of cervical carcinoma. Stage lal is defined now as depth of invasion less than or equal to 3 mm; stage la2 is defined as depth of invasion between 3 and 5 mm in depth. The width should not exceed 7 mm. Small cell carcinoma has been better delineated. An increased incidence of human papillomavirus infection and cervical intraepithelial neoplasia has been observed in patients suffering from the effects of human immunodeficiency virus, in whom invasive cervical cancers run a more aggressive course. The better understanding of pseudomalignant lesions, that is, deep cervical glands, various metaplasias and inflammatory pseudo tumours, as well as some rare tumours, enables the surgical pathologist to make a more accurate diagnosis, resulting in better patient care.

Entities:  

Mesh:

Year:  1996        PMID: 8777262

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  3 in total

1.  Fourier transform infrared (FTIR) spectral mapping of the cervical transformation zone, and dysplastic squamous epithelium.

Authors:  B R Wood; L Chiriboga; H Yee; M A Quinn; D McNaughton; M Diem
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

Review 2.  [Precancerous lesions of the uterine cervix: morphology and molecular pathology].

Authors:  L-C Horn; K Klostermann
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

3.  Genomic amplification of the human telomerase gene (hTERC) associated with human papillomavirus is related to the progression of uterine cervical dysplasia to invasive cancer.

Authors:  Hongqian Liu; Shanling Liu; He Wang; Xiaoyan Xie; Xinlian Chen; Xuemei Zhang; Youcheng Zhang
Journal:  Diagn Pathol       Date:  2012-10-30       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.